Paul Hudson: Sanofi 'least exposed' to generic competition as Big Pharma doubles down on Dupixent

Paul Schloesser

Associate Editor

As Sanofi gears to change strategies to increase Dupixent sales and add indications amid a sprawling R&D trim, CEO Paul Hudson gave some insight into …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Paul Hudson: Sanofi 'least exposed' to generic competition as Big Pharma doubles down on Dupixent

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Paul Hud­son: Sanofi 'least ex­posed' to gener­ic com­pe­ti­tion as Big Phar­ma dou­bles down on Dupix­ent

Associate Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Paul Hudson: Sanofi 'least exposed' to generic competition as Big Pharma doubles down on Dupixent